does asct still have a place in myeloma treatment?
Published 3 years ago • 429 plays • Length 4:46Download video MP4
Download video MP3
Similar videos
-
3:34
asct eligibility in myeloma patients aged ≥ 75
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline
-
1:58
with new treatment options in myeloma, is auto-sct still necessary?
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
4:04
the future of myeloma treatment and the possibility of cure
-
3:51
updated results of griffin: d-rvd vs rvd in patients with newly diagnosed multiple myeloma
-
1:39
mmr antibody titers in post-asct myeloma patients
-
2:48
can car-t therapy be used in conjunction with or instead of autologous transplantation in myeloma?
-
7:43
the efficacy of double asct for multiple myeloma
-
4:29
car-t therapy vs. asct for myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:55
asct remains at the forefront of multiple myeloma therapy
-
3:02
optimal treatment strategies for multiple myeloma
-
4:01
kenneth anderson: what are the next steps to a myeloma cure?
-
2:46
managing patients with high-risk myeloma
-
4:24
monoclonal antibodies for myeloma relapsed after asct
-
3:05
updates from the determination trial: rvd vs. autosct in patients with multiple myeloma
-
1:49
rehabilitation needs of patients with multiple myeloma undergoing car-t therapy
-
1:58
asct in the outpatient setting
-
2:00
real-world outcomes of autosct for multiple myeloma in the first-line setting